003060.Ks
003060.KS is a pharmaceutical company that develops, produces, and distributes prescription drugs and biologics.
Business. 003060.KS is a pharmaceutical company that develops, produces, and distributes prescription drugs and biologics.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
003060.KS is a pharmaceutical company that develops, produces, and distributes prescription drugs and biologics.
The company's capital structure is characterized by a debt-to-equity ratio of 0.8, indicating a moderate reliance on debt financing relative to equity. Despite holding KRW 24,392,535,690 in cash and equivalents, the firm's long-term debt of KRW 228,343,747,040 exceeds its cash reserves, resulting in a negative net cash position. This liquidity profile suggests a medium liquidity risk, as the firm's operating cash flow is negative at KRW -38,232,646,550, and capital expenditures are also negative at KRW -9,779,603,410.
Profitability metrics are not explicitly provided, but the firm's total liabilities of KRW 310,082,819,000 and total equity of KRW 285,641,734,000 suggest a relatively balanced capital structure. However, the absence of detailed profitability data such as net income or EBITDA prevents a direct comparison to industry benchmarks. The company's operating cash flow being negative raises concerns about its ability to sustain operations without external financing.
The firm's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is not possible to assess the extent of revenue diversification or exposure to specific markets.
The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of a revenue outlook and the negative operating cash flow suggest potential challenges in sustaining growth without additional capital or operational improvements.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The firm's negative net cash position is a key flag, but the low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders.
Recent events, including filings and transcripts, are not detailed in the available data. The firm's financial snapshot does not include specific references to recent regulatory actions, product launches, or strategic partnerships that could impact its performance.
- The company has a debt-to-equity ratio of 0.8, indicating a moderate reliance on debt financing.
- The firm's operating cash flow is negative, raising concerns about liquidity and sustainability.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into diversification.
- Growth trajectory is unclear due to the absence of historical revenue data and forward-looking guidance.
- The company faces medium liquidity risk but low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- 003060.KS Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Pharmaceuticalsmedium
- Economic sector— → Healthcaremedium